Bionano genomics announces publication of study in mds and aml showing utility for refined diagnostics and prognostic stratification

San diego, sept. 14, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of a study evaluating the performance of ogm for detection of cytogenetic abnormalities in myelodysplastic syndromes (mds) and acute myeloid leukemia (aml) samples. this work is the second independent study, following a recent publication from researchers at md anderson cancer center, showing that ogm enables better molecular characterization of mds. this paper extends that research to aml and the findings indicate that ogm may have an even greater impact on the characterization of aml compared to mds, which led the researchers to recommend integrating ogm into new prognostic scoring methods for both myeloid malignancies.
BNGO Ratings Summary
BNGO Quant Ranking